Traci McCarty | BioMarin Pharmaceutical, Inc. |
Jean-Jacques Bienaimé | BioMarin Pharmaceutical, Inc. |
Jeffrey Robert Ajer | BioMarin Pharmaceutical, Inc. |
Daniel K. Spiegelman | BioMarin Pharmaceutical, Inc. |
Henry J. Fuchs, M.D. | BioMarin Pharmaceutical, Inc. |
Robert A. Baffi | BioMarin Pharmaceutical, Inc. |
Alethia Young | Credit Suisse Securities (NYSE:USA) LLC |
Carlos Solorzano | Deutsche Bank Securities, Inc. |
Kerry Tang | Goldman Sachs & Co. LLC |
Joseph P. Schwartz | Leerink Partners LLC |
Christopher Raymond | Piper Jaffray |
Aspen Mori | Bank of America Merrill Lynch |
Tim Lugo | William Blair & Co. LLC |
Jeff Chen | Cowen & Co. LLC |
Gena Wang | Barclays Capital, Inc. |
Vincent Chen | Sanford C. Bernstein & Co. LLC |
Good afternoon, my name is Sarah and I will be your conference operator, today. At this time I would like to welcome everyone to the BioMarin Pharmaceutical's Third Quarter 2017 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. I would like to introduce your speaker for today, Ms.